Romayne Apcar, CEO of HCT France

Romayne Apcar, CEO of HCT France

James Thorpe, Managing Director for HCT Europe Ltd.

James Thorpe, Managing Director for HCT Europe Ltd.

The opening of a brand new manufacturing unit (500 staff, 53 plastic injection machines) in China, two years ago, marked a strategic switch for HCT (annual sales: 110 million dollars). The packaging manufacturer is now making one step further in the region by adding a new Zamac transformation unit, including a galvanizing line, to its existing facilities.

In parallel, HCT’s managing staff recently concluded a joint-venture agreement with a Chinese company specialising in plastic injection, plastic blowing, plastic extrusion. “This agreement further increases our range of industrial capabilities,” underlines Romayne Apcar, CEO of HCT France.

This new investment occurs at a moment when the company’s ownership is being transferred. Indeed, the Thorne family recently acquired the shares of Henri Tinchant, the other historical partner.

HCT should carry on this industrial strategy. Actually, Chris and James Thorpe do not hide their intention to conclude other joint-venture agreements regarding both the brush segment and the manufacturing of cosmetic components.